KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Common Equity: 2010-2024

Historic Common Equity for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to $482.8 million.

  • Emergent BioSolutions' Common Equity rose 14.58% to $582.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $582.5 million, marking a year-over-year increase of 14.58%. This contributed to the annual value of $482.8 million for FY2024, which is 25.64% down from last year.
  • As of FY2024, Emergent BioSolutions' Common Equity stood at $482.8 million, which was down 25.64% from $649.3 million recorded in FY2023.
  • Emergent BioSolutions' Common Equity's 5-year high stood at $1.6 billion during FY2021, with a 5-year trough of $482.8 million in FY2024.
  • Over the past 3 years, Emergent BioSolutions' median Common Equity value was $649.3 million (recorded in 2023), while the average stood at $839.9 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Common Equity soared by 33.29% in 2020, and later slumped by 53.21% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Common Equity (Yearly) stood at $1.5 billion in 2020, then rose by 11.07% to $1.6 billion in 2021, then decreased by 13.89% to $1.4 billion in 2022, then plummeted by 53.21% to $649.3 million in 2023, then decreased by 25.64% to $482.8 million in 2024.